JPH0738794B2 - Method for producing L-malic acid - Google Patents
Method for producing L-malic acidInfo
- Publication number
- JPH0738794B2 JPH0738794B2 JP31464486A JP31464486A JPH0738794B2 JP H0738794 B2 JPH0738794 B2 JP H0738794B2 JP 31464486 A JP31464486 A JP 31464486A JP 31464486 A JP31464486 A JP 31464486A JP H0738794 B2 JPH0738794 B2 JP H0738794B2
- Authority
- JP
- Japan
- Prior art keywords
- malic acid
- acid
- polyoxyethylene
- cells
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 title claims description 65
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 title claims description 36
- 235000011090 malic acid Nutrition 0.000 title claims description 36
- 229940116298 l- malic acid Drugs 0.000 title claims description 29
- 238000004519 manufacturing process Methods 0.000 title claims description 12
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 33
- 239000001530 fumaric acid Substances 0.000 claims description 16
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 16
- 239000007864 aqueous solution Substances 0.000 claims description 14
- 108010036781 Fumarate Hydratase Proteins 0.000 claims description 12
- 102100036160 Fumarate hydratase, mitochondrial Human genes 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 39
- -1 Polyoxyethylene Polymers 0.000 description 22
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 21
- 239000001384 succinic acid Substances 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000000034 method Methods 0.000 description 14
- 239000006227 byproduct Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 7
- 229940099690 malic acid Drugs 0.000 description 7
- 239000001630 malic acid Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000006911 enzymatic reaction Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 235000011121 sodium hydroxide Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 4
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 4
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000007086 side reaction Methods 0.000 description 4
- 229940035044 sorbitan monolaurate Drugs 0.000 description 4
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 4
- 239000001570 sorbitan monopalmitate Substances 0.000 description 4
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 4
- 239000001587 sorbitan monostearate Substances 0.000 description 4
- 235000011076 sorbitan monostearate Nutrition 0.000 description 4
- 229940035048 sorbitan monostearate Drugs 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 150000003431 steroids Chemical group 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 229960000344 thiamine hydrochloride Drugs 0.000 description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 2
- 239000011747 thiamine hydrochloride Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- LTSWUFKUZPPYEG-UHFFFAOYSA-N 1-decoxydecane Chemical compound CCCCCCCCCCOCCCCCCCCCC LTSWUFKUZPPYEG-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- OUUCZGCOAXRCHN-UHFFFAOYSA-N 1-hexadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC OUUCZGCOAXRCHN-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- HANWHVWXFQSQGJ-UHFFFAOYSA-N 1-tetradecoxytetradecane Chemical compound CCCCCCCCCCCCCCOCCCCCCCCCCCCCC HANWHVWXFQSQGJ-UHFFFAOYSA-N 0.000 description 1
- CSHOPPGMNYULAD-UHFFFAOYSA-N 1-tridecoxytridecane Chemical compound CCCCCCCCCCCCCOCCCCCCCCCCCCC CSHOPPGMNYULAD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IEZDTNCUMWPRTD-UHFFFAOYSA-N 346704-04-9 Chemical compound [O-][N+](=O)C1=CC=C(N2CCNCC2)C=C1N1CCCCC1 IEZDTNCUMWPRTD-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241000186146 Brevibacterium Species 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- PASCVNXEVINGGG-UHFFFAOYSA-N Mollic acid Natural products CC(CCC=C(C)C)C1CCC2(C)C3CCC4C(C)(C(O)CC(O)C45CC35CCC12C)C(=O)O PASCVNXEVINGGG-UHFFFAOYSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000319304 [Brevibacterium] flavum Species 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940074096 monoolein Drugs 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 229940048098 sodium sarcosinate Drugs 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 229940045946 sodium taurodeoxycholate Drugs 0.000 description 1
- 229960000776 sodium tetradecyl sulfate Drugs 0.000 description 1
- WDFRNBJHDMUMBL-OICFXQLMSA-M sodium;(4r)-4-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)CC1 WDFRNBJHDMUMBL-OICFXQLMSA-M 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- YXHRQQJFKOHLAP-FVCKGWAHSA-M sodium;2-[[(4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 YXHRQQJFKOHLAP-FVCKGWAHSA-M 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- AYFACLKQYVTXNS-UHFFFAOYSA-M sodium;tetradecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCCCS([O-])(=O)=O AYFACLKQYVTXNS-UHFFFAOYSA-M 0.000 description 1
- UPUIQOIQVMNQAP-UHFFFAOYSA-M sodium;tetradecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCOS([O-])(=O)=O UPUIQOIQVMNQAP-UHFFFAOYSA-M 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- CUXKZYSCZCNPNX-UHFFFAOYSA-N tetradecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCCCC[NH3+] CUXKZYSCZCNPNX-UHFFFAOYSA-N 0.000 description 1
- CEYYIKYYFSTQRU-UHFFFAOYSA-M trimethyl(tetradecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)C CEYYIKYYFSTQRU-UHFFFAOYSA-M 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
【発明の詳細な説明】 技術分野 本発明は、L−リンゴ酸の製造法に関するものであり、
更に詳しくは、フマラーゼ活性を有する微生物に対し、
その活性を保持したまま、副反応であるコハク酸の生成
に関与する酵素活性を抑制することにより、L−リンゴ
酸を効率的に製造する方法に関する。TECHNICAL FIELD The present invention relates to a method for producing L-malic acid,
More specifically, for microorganisms having fumarase activity,
The present invention relates to a method for efficiently producing L-malic acid by suppressing the enzyme activity involved in the production of succinic acid which is a side reaction while maintaining its activity.
従来の技術及びその課題 従来、フマラーゼによるフマール酸又はその塩からのL
−リンゴ酸の製造に関しては、フマラーゼ活性を有する
微生物菌体をそのまま、もしくは固定化等の処理を行つ
てから用いる方法が知られている(特公昭37−4511号、
同44−1191号各公報等)。本発明者らもブレビバクテリ
ウム属細菌を用いた製法を確立している(特開昭61−26
5096号明細書)。Conventional technology and its problems Conventionally, L from fumaric acid or its salt by fumarase
-For the production of malic acid, a method is known in which a microbial cell having a fumarase activity is used as it is or after being subjected to treatment such as immobilization (Japanese Patent Publication No. 37-4511).
No. 44-1191, etc.). The present inventors have also established a production method using Brevibacterium bacteria (Japanese Patent Laid-Open No. 61-26).
5096).
しかしながら、これらの方法は微生物菌体を用いるため
にフマール酸よりコハク酸が副生することがしばしばみ
とめられ、この副生されたコハク酸をL−リンゴ酸から
効率よく分離することは困難なことから、フマール酸か
らのコハク酸の副生を抑制することが工業的製法として
重要となる。However, in these methods, succinic acid is often found as a by-product of fumaric acid due to the use of microbial cells, and it is difficult to efficiently separate this succinic acid by-produced from L-malic acid. Therefore, it is important as an industrial production method to suppress the by-production of succinic acid from fumaric acid.
コハク酸の副生を抑制する方法としては、固定化微生物
を有機溶媒に接触させる方法(特公昭52−8396号公
報)、固定化微生物を胆汁酸に接触させる方法(特公昭
52−31952号公報)が知られている。As a method for suppressing the by-production of succinic acid, a method of contacting an immobilized microorganism with an organic solvent (Japanese Patent Publication No. 52-8396) and a method of contacting the immobilized microorganism with bile acid (Japanese Patent Publication No.
No. 52-31952) is known.
しかしながらこれらの方法は、有機溶媒を用いる場合に
は溶媒の性質上、安全等に格別の配慮が必要なことか
ら、特殊な装置類が必要となること、胆汁酸を用いる場
合には、胆汁酸が高価なこと、処理時間が長いこと等、
工業的には未だ問題点を残しており、より簡便な処理法
が望まれていた。However, these methods require special equipment when using an organic solvent due to the nature of the solvent, and therefore require special equipment.When using bile acid, bile acid is used. Is expensive, the processing time is long, etc.
Industrially, there are still problems, and a simpler processing method has been desired.
発明の要旨 本発明は、フマラーゼを含有する菌体もしくはその処理
物の存在下フマール酸又はその塩からL−リンゴ酸を酵
素反応により製造する方法において、該菌体もしくはそ
の処理物が界面活性剤を含有したL−リンゴ酸もしくは
その塩の水溶液中で加熱処理したものであることを特徴
とするL−リンゴ酸の製造法を提供するものである。SUMMARY OF THE INVENTION The present invention provides a method for producing L-malic acid by enzymatic reaction from fumaric acid or a salt thereof in the presence of a fumarase-containing bacterium or a treated product thereof, wherein the bacterium or the treated product is a surfactant. The present invention provides a method for producing L-malic acid, which is characterized by being heat-treated in an aqueous solution of L-malic acid or a salt thereof containing.
発明の効果 本発明の方法によれば、フマラーゼを含有する菌体もし
くはその処理物の存在下に酵素反応させて、フマール酸
又はその塩からL−リンゴ酸を製造する際のコハク酸の
副生を著しく低くすることができる。EFFECTS OF THE INVENTION According to the method of the present invention, a succinic acid by-product is produced when L-malic acid is produced from fumaric acid or a salt thereof by enzymatic reaction in the presence of fumarase-containing cells or a treated product thereof. Can be significantly reduced.
又、このコハク酸副生を抑制する加熱処理は、界面活性
剤とL−リンゴ酸もしくはその塩の水溶液を併用するこ
とで、短時間でまた加熱処理を比較的低温で行える様に
なり、工業的方法として有利になる。The heat treatment for suppressing the succinic acid by-product can be performed in a short time and at a relatively low temperature by using a surfactant and an aqueous solution of L-malic acid or a salt thereof together. It becomes advantageous as a target method.
発明の詳細な説明 本発明において用いられるフマラーゼ活性を有する菌体
としては、例えば微工研に寄託されているブレビバクテ
リウム・フラバムMJ−233(FERM BP−1497)(特公昭57
−26755号公報参照)の菌体及びこの菌よりα−アミノ
−n−酪酸耐性株として取得したMJ−233−AB−41(FER
M BP−1498)(特公昭59−28398号公報参照)の菌体等
がある。Detailed Description of the Invention Examples of the bacterium having a fumarase activity used in the present invention include Brevibacterium flavum MJ-233 (FERM BP-1497) (Japanese Patent Publication No.
-26755) and MJ-233-AB-41 (FER, which was obtained from this fungus as an α-amino-n-butyric acid resistant strain.
M BP-1498) (see Japanese Examined Patent Publication No. 59-28398).
これらの菌体は遊離菌体のまま用いることができるが、
更には該菌体、或いはその含有する酵素(フマラーゼ)
を公知の方法で固定化したものを反応に供してもよい。
この固定化物の副反応抑制処理である加熱処理は固定化
の前後いずれでもよい。固定化としては、この種の菌体
又は酵素の固定化に通常用いられる方法が使用可能で、
例えばポリアクリルアミドゲル、カラギーナンゲル、膜
状高分子等に固定化して用いられる。Although these cells can be used as they are,
Furthermore, the bacterial cell or the enzyme (fumarase) contained therein
What was fixed by the well-known method may be used for reaction.
The heat treatment, which is a side reaction suppressing treatment for the immobilization product, may be performed before or after the immobilization. As the immobilization, a method usually used for immobilizing this type of bacterial cell or enzyme can be used,
For example, it is used after being immobilized on polyacrylamide gel, carrageenan gel, membrane polymer, or the like.
コハク酸副生の抑制処理条件としては、加熱温度30〜60
℃が用いられるが好ましくは35℃を越え55℃まで、pHは
好ましくは4〜10、より好ましくはpH5〜9、L−リン
ゴ酸濃度は好ましくは0.01〜5モル、より好ましくは0.
01〜0.3モル、反応時間は菌体濃度によつても異なるが
通常10分〜3時間用いられる。As a condition for suppressing the succinic acid byproduct, the heating temperature is 30 to 60.
C. is used, but preferably more than 35.degree. C. to 55.degree. C., pH is preferably 4-10, more preferably pH 5-9, L-malic acid concentration is preferably 0.01-5 mol, more preferably 0.
The reaction time is usually from 0.1 to 0.3 mol, and the reaction time varies depending on the cell concentration, but is usually 10 minutes to 3 hours.
本発明に用いられる界面活性剤としては、例えば、ドデ
シルトリメチルアンモニウムクロリド、テトラデシルト
リメチルアンモニウムクロリド、セチルトリメチルアン
モニウムブロミド、ドデシルピリジニウムブロミド、セ
チルピリジニウムクロリド、テトラデシルアンモニウム
ブロミド等の陽イオン性界面活性剤、ドデシル硫酸ナト
リウム、テトラデシル硫酸ナトリウム、ドデシルスルホ
ン酸ナトリウム、テトラデシルスルホン酸ナトリウム、
ドデシルベンゼンスルホン酸ナトリウム、ドデシル−N
−サルコシン酸ナトリウム等の陰イオン性界面活性剤、
ポリオキシエチレン(n)デシルエーテル、ポリオキシ
エチレン(n)ドデシルエーテル、ポリオキシエチレン
(n)トリデシルエーテル、ポリオキシエチレン(n)
テトラデシルエーテル、ポリオキシエチレン(n)セチ
ルエーテル、ポリオキシエチレン(n)ステアリルエー
テル、ポリオキシエチレン(n)オレイルエーテル、ポ
リオキシエチレン(n)セチルステアリルエーテル、ポ
リオキシエチレン(n)パラーtert−オクチルフエニル
エーテル、ポリオキシエチレン(n)パラーオクチルフ
エニルエーテル、ポリオキシエチレン(n)パラーノニ
ルフエニルエーテル、モノラウリン酸ソルビタン、モノ
パルミチン酸ソルビタン、モノステアリン酸ソルビタ
ン、モノオレイン酸ソルビタン、ポリオキシエチレン
(n)モノラウリン酸ソルビタン、ポリオキシエチレン
(n)モノパルミチン酸ソルビタン、ポリオキシエチレ
ン(n)モノステアリン酸ソルビタン、ポリオキシエチ
レン(n)モノオレイン酸ソルビタン等の非イオン性界
面活性剤、パルミトイルリゾレシチン、ドデシル−N−
ベタイン、ステアリル−N−ベタイン、ドデシル−β−
アラニン等の両性界面活性剤、コール酸ナトリウム、デ
オキシコール酸ナトリウム、ケノデオキシコール酸ナト
リウム、タウロコール酸ナトリウム、タウロデオキシコ
ール酸ナトリウム、ジギトニン等のステロイド骨格を有
する界面活性剤などが例示できる。ただしポリオキシエ
チレンの後の(n)は例示した物質がオキシエチレン
(−CH2CH2O−)単位の数(n)が異なる一群の化合物
を包含していることを意味する。Examples of the surfactant used in the present invention include dodecyltrimethylammonium chloride, tetradecyltrimethylammonium chloride, cetyltrimethylammonium bromide, dodecylpyridinium bromide, cetylpyridinium chloride, and cationic surfactants such as tetradecylammonium bromide. Sodium dodecyl sulfate, sodium tetradecyl sulfate, sodium dodecyl sulfonate, sodium tetradecyl sulfonate,
Sodium dodecylbenzenesulfonate, dodecyl-N
An anionic surfactant such as sodium sarcosinate,
Polyoxyethylene (n) decyl ether, polyoxyethylene (n) dodecyl ether, polyoxyethylene (n) tridecyl ether, polyoxyethylene (n)
Tetradecyl ether, polyoxyethylene (n) cetyl ether, polyoxyethylene (n) stearyl ether, polyoxyethylene (n) oleyl ether, polyoxyethylene (n) cetyl stearyl ether, polyoxyethylene (n) para-tert- Octyl phenyl ether, polyoxyethylene (n) para-octyl phenyl ether, polyoxyethylene (n) para-nonyl phenyl ether, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, polyoxy Ethylene (n) sorbitan monolaurate, polyoxyethylene (n) sorbitan monopalmitate, polyoxyethylene (n) sorbitan monostearate, polyoxyethylene (n) monoolein Nonionic surfactants such as sorbitan acid, palmitoyl lysolecithin, dodecyl-N-
Betaine, stearyl-N-betaine, dodecyl-β-
Examples thereof include amphoteric surfactants such as alanine, and surfactants having a steroid skeleton such as sodium cholate, sodium deoxycholate, sodium chenodeoxycholate, sodium taurocholate, sodium taurodeoxycholate, and digitonin. However, (n) after polyoxyethylene means that the exemplified substances include a group of compounds having different numbers (n) of oxyethylene (—CH 2 CH 2 O—) units.
これらの界面活性剤の中では、陽イオン性界面活性剤、
非イオン性界面活性剤、ステロイド骨格を有する界面活
性剤が好ましく、特にセチルトリメチルアンモニウムブ
ロミド、セチルピリジニウムクロリド、ポリオキシエチ
レン(n)パラ−tert−オクチルフエニルエーテル、モ
ノラウリン酸ソルビタン、モノパルミチン酸ソルビタ
ン、モノステアリン酸ソルビタン、モノオレイン酸ソル
ビタン、ポリオキシエチレン(n)モノラウリン酸ソル
ビタン、ポリオキシエチレン(n)モノパルミチン酸ソ
ルビタン、ポリオキシエチレン(n)モノステアリン酸
ソルビタン、ポリオキシエチレン(n)モノオレイン酸
ソルビタン、コール酸ナトリウム、デオキシコール酸ナ
トリウム等が好ましい。Among these surfactants, cationic surfactants,
Nonionic surfactants and surfactants having a steroid skeleton are preferable, and particularly cetyltrimethylammonium bromide, cetylpyridinium chloride, polyoxyethylene (n) para-tert-octylphenyl ether, sorbitan monolaurate, sorbitan monopalmitate. , Sorbitan monostearate, sorbitan monooleate, polyoxyethylene (n) sorbitan monolaurate, polyoxyethylene (n) sorbitan monopalmitate, polyoxyethylene (n) sorbitan monostearate, polyoxyethylene (n) mono Preference is given to sorbitan oleate, sodium cholate, sodium deoxycholate and the like.
これらの界面活性剤の添加濃度は、界面活性剤の種類に
もよるが0.005%(wt/vol)以上が用いられるが、好ま
しくは0.01〜2%、特に好ましくは0.02〜1%である。The addition concentration of these surfactants is 0.005% (wt / vol) or more, though it depends on the kind of the surfactant, but it is preferably 0.01 to 2%, particularly preferably 0.02 to 1%.
上記コハク酸副生の抑制処理の加熱温度は、上記範囲よ
り高温では目的反応のフマラーゼ活性まで失活するの
で、また低温では副反応の抑制効果が減ずるので不適当
となる。またL−リンゴ酸濃度については、上記より高
濃度では効果が飽和し不経済であり、低濃度では副反応
のみを抑制する効果が出せなくなる。When the heating temperature for the succinic acid by-product suppression treatment is higher than the above range, the fumarase activity of the desired reaction is inactivated, and at low temperatures, the side reaction suppression effect is reduced, which is unsuitable. Regarding the L-malic acid concentration, if the concentration is higher than the above, the effect is saturated and it is uneconomical, and if the concentration is low, the effect of suppressing only side reactions cannot be obtained.
上述の様にして得た菌体又はその固定化物はコハク酸副
生活性が著しく低下している為、該菌体又は固定化物を
用いたL−リンゴ酸の生産に際しては、コハク酸の副生
を抑制しうることが明らかとなつた。それ故、この処理
菌体又は固定化物の存在下にフマール酸又はそのナトリ
ウム、アンモニウム等のフマール酸塩から効率的にL−
リンゴ酸を生産することができる。Since the succinic acid by-product of the bacterial cell or its immobilized product obtained as described above is remarkably reduced, when producing L-malic acid using the bacterial cell or the immobilized product, a by-product of succinic acid is produced. It has become clear that this can be suppressed. Therefore, in the presence of the treated cells or immobilized product, fumaric acid or its fumaric acid salt such as sodium or ammonium can be efficiently converted to L-.
Can produce malic acid.
この酵素反応は約15〜60℃の温度範囲で実施することが
可能であるが、フマラーゼの安定性を考慮して20〜55℃
で実施するのが望ましい。この酵素反応は水溶媒中で行
なわれるが、水の他にリン酸緩衝液、トリス塩酸緩衝液
等の溶媒を10〜500mMの濃度で用いることもできる。
又、反応液のpHを4〜10に調節するため水酸化カリウ
ム、水酸化ナトリウム、水酸化アンモニウム等のアルカ
リ類、塩酸、硫酸等の無機酸を添加することもできる。This enzymatic reaction can be carried out in the temperature range of about 15 to 60 ° C, but considering the stability of fumarase, it is 20 to 55 ° C.
It is desirable to carry out. This enzymatic reaction is carried out in a water solvent, but it is also possible to use a solvent such as a phosphate buffer or Tris-HCl buffer at a concentration of 10 to 500 mM in addition to water.
Further, in order to adjust the pH of the reaction solution to 4 to 10, alkalis such as potassium hydroxide, sodium hydroxide and ammonium hydroxide, and inorganic acids such as hydrochloric acid and sulfuric acid can be added.
フマール酸又はその塩の反応時の使用量には特に制限は
ないが、一般には0.5〜30%(wt/vol)の範囲で使用す
るのが適当である。又、コハク酸副生の抑制処理を施し
たフマラーゼを含有する菌体もしくはその処理物の使用
量も特に制限されるものではないが、一般に0.5〜10%
(wt/vol)の範囲で使用することができる。The amount of fumaric acid or a salt thereof used during the reaction is not particularly limited, but it is generally suitable to use it in the range of 0.5 to 30% (wt / vol). In addition, the amount of the microbial cells containing fumarase that has been subjected to a succinic acid by-product suppression treatment or a treated product thereof is not particularly limited, but is generally 0.5 to 10%.
It can be used in the range of (wt / vol).
該処理物を用いてフマール酸と水を酵素反応せしめて得
られる反応液中に生成したL−リンゴ酸の分離・精製は
イオン交換樹脂、活性炭等による吸着、脱着等の公知の
方法により行なうことができる。Separation and purification of L-malic acid produced in the reaction solution obtained by enzymatically reacting fumaric acid with water using the treated product should be carried out by a known method such as adsorption or desorption with an ion exchange resin, activated carbon or the like. You can
本発明の方法によれば、菌体内に含まれるフマラーゼ活
性を損なうことなく、コハク酸の副生のみを除去した菌
体又はその固定化物を用いるので、この処理菌体をL−
リンゴ酸の生産に使用すれば対フマール酸収率が著しく
向上する。従つて本発明はL−リンゴ酸の工業的生産に
大いに貢献する。According to the method of the present invention, since the microbial cells obtained by removing only the by-product of succinic acid or its immobilized product are used without impairing the fumarase activity contained in the microbial cells, this treated microbial cell is
When used for the production of malic acid, the yield of fumaric acid is significantly improved. Therefore, the present invention greatly contributes to the industrial production of L-malic acid.
以下、本発明の実施例を示し、本発明を更に詳しく説明
するが、本発明はこれに限定されるものではない。Hereinafter, the present invention will be described in more detail by showing Examples of the present invention, but the present invention is not limited thereto.
実験例 参考例1 第1表に示した組成の培地50mlを500ml容三角フラスコ
に分注し、120℃、15分間加圧滅菌したものにエタノー
ルを2容量%添加後、前記のブレビバクテリウム・フラ
バムMJ−233(FERM BP−1498)を一白金耳量植菌し、30
℃で24時間振とう培養を行なつた。Experimental Example Reference Example 1 50 ml of a medium having the composition shown in Table 1 was dispensed into a 500 ml Erlenmeyer flask and autoclaved at 120 ° C. for 15 minutes, and then 2% by volume of ethanol was added thereto. Flavum MJ-233 (FERM BP-1498) was inoculated with one platinum loop, and
Shaking culture was carried out at ℃ for 24 hours.
この培養液20mlを2容ジヤーフアーメンター中の第2
表に示した培地1に接種し、33℃、pH7.6、通気量1vv
mの条件にて培養し、エタノール濃度が1〜1.5容量%に
保たれるようにエタノールを断続的に添加し、30時間培
養を行なつた。20 ml of this culture solution was added to the second volume in a 2-volume jar fermenter.
Inoculated to the medium 1 shown in the table, 33 ℃, pH7.6, aeration 1vv
The cells were cultured under the condition of m, ethanol was intermittently added so that the ethanol concentration was maintained at 1 to 1.5% by volume, and the cells were cultured for 30 hours.
培養終了後、培養液を遠心分離(6,000rpm、15分)して
得た菌体を供試菌体とした。After completion of the culture, the culture solution was centrifuged (6,000 rpm, 15 minutes) to obtain the cells as test cells.
カセイソーダにてpH7.0に調整した0.2モル/のL−リ
ンゴ酸を含有する水溶液に、第3表に示す各種界面活性
剤をそれぞれ0.2%(wt/vol)添加した。こうして得ら
れたそれぞれの水溶液を50mlづつ採り、上記で得た菌体
2.5gづつをそれぞれに懸濁した。次いで、これらを45℃
で2時間加熱処理し、それぞれ遠心分離して集菌した。0.2% (wt / vol) of each surfactant shown in Table 3 was added to an aqueous solution containing 0.2 mol / L-malic acid adjusted to pH 7.0 with caustic soda. Take 50 ml of each of the thus obtained aqueous solutions and obtain the bacterial cells obtained above.
2.5 g each was suspended in each. Then these are 45 ℃
Heat treatment was carried out for 2 hours, and the cells were collected by centrifugation.
かくして得られた加熱処理菌体それぞれ2.5gを、予めカ
セイソーダでpH7.0に調整した1.0モル/フマール酸水
溶液50mlに懸濁し、45℃で2時間酵素反応させた。2.5 g of each of the heat-treated cells thus obtained was suspended in 50 ml of a 1.0 mol / fumaric acid aqueous solution which had been adjusted to pH 7.0 with caustic soda, and enzymatically reacted at 45 ° C. for 2 hours.
各反応液中の生成L−リンゴ酸及び副生コハク酸量を、
高速液体クロマトグラフイーにて定量した。その結果
を、界面活性剤無添加とした以外は上記と同様に菌体の
加熱処理を行いこれを用いて上記と同様の酵素反応を行
つた時のL−リンゴ酸及びコハク酸生成量をそれぞれ10
0とした時の割合で第3表に示した。The amount of produced L-malic acid and by-product succinic acid in each reaction solution is
It was quantified by high performance liquid chromatography. As a result, the amount of L-malic acid and succinic acid produced when the same enzymatic reaction as the above was carried out by heat-treating the cells in the same manner as above except that the surfactant was not added, respectively. Ten
The ratio when 0 is shown in Table 3.
第1表 尿素 4.0 g 硫酸アンモニウム 14.0 g KH2PO4 0.5 g K2HPO4 0.5 g MgSO4・7H2O 0.5 g FeSO4・7H2O 6.0mg MnSO4・4〜6H2O 6.0mg 酵母エキス 1.0 g カザミノ酸 1.0 g ビオチン 200 μg チアミン塩酸塩 100 μg 蒸留水 1000 ml pH 7.6 第2表 硫酸アンモニウム 23.0 g KH2PO4 0.5 g K2HPO4 0.5 g MgSO4・7H2O 0.5 g FeSO4・7H2O 20 mg MnSO4・4〜6H2O 20 mg 酵母エキス 3 g カザミノ酸 3 g ビオチン 200 μg チアミン塩酸塩 100 μg 蒸留水 1000 ml 参考例2 参考例1と同様にして供試菌体を得た。予めカセイソー
ダにてpHを7.0に調整した「Tween 20」をそれぞれ第4
表に示す濃度で含有する0.2モル/濃度のL−リンゴ
酸水溶液50mlに上記供試菌体をそれぞれ2.5g加え、これ
をそれぞれ45℃で2時間加熱処理した。その後、遠心分
離によりそれぞれ集菌した。Table 1 Urea 4.0 g Ammonium sulfate 14.0 g KH 2 PO 4 0.5 g K 2 HPO 4 0.5 g MgSO 4 / 7H 2 O 0.5 g FeSO 4 / 7H 2 O 6.0 mg MnSO 4 / 4-6H 2 O 6.0 mg Yeast extract 1.0 g Casamino acid 1.0 g Biotin 200 μg Thiamine hydrochloride 100 μg Distilled water 1000 ml pH 7.6 Table 2 Ammonium sulfate 23.0 g KH 2 PO 4 0.5 g K 2 HPO 4 0.5 g MgSO 4 / 7H 2 O 0.5 g FeSO 4 / 7H 2 O 20 mg MnSO 4・ 4-6H 2 O 20 mg Yeast extract 3 g Casamino acid 3 g Biotin 200 μg Thiamine hydrochloride 100 μg Distilled water 1000 ml Reference Example 2 Test cells were obtained in the same manner as in Reference Example 1. "Tween 20" whose pH has been adjusted to 7.0 with caustic soda is the fourth
2.5 g of each of the above-mentioned test cells was added to 50 ml of a 0.2 mol / concentration L-malic acid aqueous solution contained at the concentration shown in the table, and each was heat-treated at 45 ° C. for 2 hours. Then, the cells were collected by centrifugation.
かくして得られた加熱処理菌体を用いた以外は、参考例
1と同様にフマール酸水液培を酵素反応させ、得られた
反応液中のL−リンゴ酸及び副生コハク酸を参考例1と
同様に測定し、その結果を第4表に示した。The fumaric acid aqueous solution was enzymatically reacted in the same manner as in Reference Example 1 except that the heat-treated bacterial cells thus obtained were used, and L-malic acid and by-product succinic acid in the obtained reaction solution were used in Reference Example 1. The measurement was conducted in the same manner as above, and the results are shown in Table 4.
参考例3 参考例1と同様にして供試菌体を得た。この菌体2.5gづ
つを、「Tween 20」を0.2%(wt/vol)含む0.2モル/
の濃度のリンゴ酸水溶液50ml(pH7.0)に加え、第5
表に示す各処理温度で2時間加熱処理をそれぞれ行つ
た。 Reference Example 3 Test cells were obtained in the same manner as in Reference Example 1. 2.5 mol each of these cells contained 0.2% (wt / vol) of "Tween 20" 0.2 mol /
Add 50 ml of malic acid aqueous solution (pH 7.0) of
The heat treatment was performed for 2 hours at each treatment temperature shown in the table.
この加熱処理菌体をそれぞれ集菌して用いた以外は参考
例1と同様にフマール酸水溶液を酵素反応させ、得られ
た反応液中のL−リンゴ酸及び副生コハク酸を参考例1
と同様に測定し、その結果を第5表に示した。L-malic acid and by-product succinic acid in the reaction solution obtained by enzymatically reacting an aqueous solution of fumaric acid in the same manner as in Reference Example 1 except that the heat-treated cells were collected and used.
Measurement was carried out in the same manner as above, and the results are shown in Table 5.
参考例4 参考例1と同様にして得た供試菌体2.5gづつを、「Twee
n 20」を0.2%(wt/vol)含む0.2モル/の濃度のL
−リンゴ酸水溶液50ml(pH7.0)に懸濁し、45℃にて第
6表に示す時間、加熱処理を行つた。 Reference Example 4 2.5 g each of the test cells obtained in the same manner as in Reference Example 1 was added to "Twee
n 20 "containing 0.2% (wt / vol) of 0.2 mol / concentration of L
-Suspended in 50 ml of an aqueous solution of malic acid (pH 7.0), and heat-treated at 45 ° C for the time shown in Table 6.
得られた加熱処理菌体をそれぞれ遠心分離により集菌
し、これらの菌を用いた以外は参考例1と同様にフマー
ル酸水溶液を酵素反応させ、得られた反応液中のL−リ
ンゴ酸及び副生コハク酸を参考例1と同様に測定し、そ
の結果を第6表に示した。The obtained heat-treated bacterial cells were collected by centrifugation, and the fumaric acid aqueous solution was enzymatically reacted in the same manner as in Reference Example 1 except that these bacteria were used to obtain L-malic acid and L-malic acid in the reaction solution. The succinic acid by-product was measured in the same manner as in Reference Example 1, and the results are shown in Table 6.
実施例1 参考例1と同様にして得た供試菌体2.5gを、「Tween 2
0」を0.2%(wt/vol)含む0.2モル/濃度のL−リン
ゴ酸水溶液(カセイソーダでpH7.0に調整)50mlに懸濁
し、45℃で2時間加熱処理し、その後遠心分離により集
菌した。 Example 1 2.5 g of the test cells obtained in the same manner as in Reference Example 1 was added to "Tween 2
Suspended in 50 ml of 0.2 mol / concentration L-malic acid aqueous solution (pH 7.0 adjusted with caustic soda) containing 0.2% (wt / vol) of "0", heat treated at 45 ° C for 2 hours, and then collected by centrifugation. did.
この菌体全量を1モル/濃度のフマール酸水溶液50ml
(カセイソーダでpH7.0に調整)に懸濁し、45℃で2時
間酵素反応させた。反応終了後反応液中に生成したL−
リンゴ酸及びコハク酸量を高速液体クロマトグラフイー
にて定量したところ原料フマール酸に対するモル収率で
L−リンゴ酸が78%(39ミリモル)、コハク酸が0.05%
(2.5ミリモル)未満生成していた。50 ml of 1 mol / concentration fumaric acid aqueous solution
(PH 7.0 was adjusted with caustic soda), and the enzyme reaction was carried out at 45 ° C. for 2 hours. L- generated in the reaction solution after completion of the reaction
The amounts of malic acid and succinic acid were quantified by high performance liquid chromatography, and the molar yield was 78% (39 mmol) of L-malic acid and 0.05% of succinic acid based on the starting fumaric acid.
Less than (2.5 mmol) was formed.
この溶液を6規定HCl溶液にてpHを約2に調整後、強塩
基生樹脂(ローム・アンド・ハース社製)「アンバーラ
イトIRA−400」、R2CO3型)を充てんしたカラムに通し
L−リンゴ酸を樹脂に吸着させた。次に1規定炭酸アン
モニウムにて溶出後濃縮し、L−リンゴ酸の粗結晶を析
出させた。これをアセトンで洗浄し乾燥した結果、L−
リンゴ酸の結晶2.8gを得た。The pH of this solution was adjusted to about 2 with a 6N HCl solution, and the solution was passed through a column filled with a strong base resin (Amberlite IRA-400, manufactured by Rohm and Haas Co., R 2 CO 3 type). L-malic acid was adsorbed on the resin. Next, it was eluted with 1N ammonium carbonate and then concentrated to precipitate crude crystals of L-malic acid. After washing this with acetone and drying, L-
2.8 g of malic acid crystals were obtained.
Claims (1)
理物の存在下フマール酸又はその塩からL−リンゴ酸を
酸素反応により製造する方法において、該菌体もしくは
その処理物が界面活性剤を含有したL−リンゴ酸もしく
はその塩の水溶液中で加熱処理したものであることを特
徴とするL−リンゴ酸の製造法。1. A method for producing L-malic acid from fumaric acid or a salt thereof by an oxygen reaction in the presence of a fumarase-containing bacterium or a treated product thereof, wherein the bacterium or the treated product contains a surfactant. The method for producing L-malic acid is characterized by being heat-treated in an aqueous solution of L-malic acid or a salt thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP31464486A JPH0738794B2 (en) | 1986-12-24 | 1986-12-24 | Method for producing L-malic acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP31464486A JPH0738794B2 (en) | 1986-12-24 | 1986-12-24 | Method for producing L-malic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63160590A JPS63160590A (en) | 1988-07-04 |
| JPH0738794B2 true JPH0738794B2 (en) | 1995-05-01 |
Family
ID=18055809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP31464486A Expired - Lifetime JPH0738794B2 (en) | 1986-12-24 | 1986-12-24 | Method for producing L-malic acid |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0738794B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4933338B2 (en) * | 2007-04-20 | 2012-05-16 | サトーホールディングス株式会社 | Display piece for seedling growing container |
-
1986
- 1986-12-24 JP JP31464486A patent/JPH0738794B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPS63160590A (en) | 1988-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS5937951B2 (en) | Biological production of amides | |
| EP0527553B1 (en) | Process for producing r(-)-mandelic acid and derivative thereof | |
| EP0610048A2 (en) | Process for producing optically active alpha-hydrocarboxylic acid having phenyl group | |
| EP0610049A2 (en) | Process for producing optically active alpha-hydroxycarboxylic acid having phenyl group | |
| JPS62257386A (en) | Method for preserving nitrile hydrating activity | |
| JPH0448435B2 (en) | ||
| JPS6291189A (en) | Microbiological production of amide | |
| JP2696424B2 (en) | Method for producing R (-)-mandelic acid | |
| JPH0738794B2 (en) | Method for producing L-malic acid | |
| JP3081649B2 (en) | Process for producing S-(+)-mandelamide and its derivatives | |
| JP2696436B2 (en) | Method for producing R (-)-mandelic acid | |
| JPS633599B2 (en) | ||
| JP3012990B2 (en) | Method for producing D-aspartic acid | |
| JP4259642B2 (en) | Method for producing L-ribulose | |
| JPH022597B2 (en) | ||
| JP2721536B2 (en) | Method for obtaining D-β-hydroxy amino acid | |
| JP3313000B2 (en) | Process for producing S-(+)-mandelamide and its derivatives | |
| JPS6349090A (en) | Production of calcium l-malate | |
| JP3277930B2 (en) | Method for producing D-malic acid | |
| JP3011472B2 (en) | Production method of indigo by enzymatic method | |
| JP2708536B2 (en) | Rhodococcus bacteria and method for producing 2-hydroxybutyric acid using the same | |
| JPH0480678B2 (en) | ||
| JPH0851989A (en) | Method for isomerizing maleic acid | |
| JP3304959B2 (en) | Method for producing D-malic acid | |
| JP2502990B2 (en) | <1> -Process for producing malic acid |